ClinicalTrials.gg
RecruitingNCT06123715PROVISIONUpdated Nov 13, 2026

Perioperative Vitamin C to Reduce Persistent Pain After Total Knee Arthroplasty

A Phase 3 interventional study of Vitamin C and Placebo in Chronic Pain, Knee Pain Chronic and Post Operative Pain, sponsored by University Health Network, Toronto. Recruiting at 3 sites in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-13.

Sponsored by University Health Network, Toronto · Phase 3, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Apr 2024; still recruiting 2 years 7 months later.
Updated Nov 13, 2026Primary completion movedStudy completion moved+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
3,216
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 19 studies in Chronic Pain by University Health Network, Toronto — 6 open to participants now, 10 under way, 3 of them phase 3. Chronic Pain · University Health Network, Toronto.

Planned enrollment
Largest of 15
3,216 · median 56
Started
2024
with 1 other
Phase 3
3 of 19
2 open now
Registered
15th of 19
by date

Among the 19 studies in Chronic Pain by University Health Network, Toronto, this one has the largest planned enrollment of the 15 interventional ones that give a count, is one of 2 that started in 2024, is one of 3 in phase 3, and was the 15th registered.

Chronic Pain

3,230 studies on the registry are indexed under Chronic Pain; 728 are open to participants now.

Browse Chronic Pain studies →

Open to participants now

6 of the 19 studies in Chronic Pain by University Health Network, Toronto are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 486 Chronic Pain studies recruiting now, 239 (49%) set no upper age limit and 173 (36%) stop at 75 or younger; 43 take children under 18; 64 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Chronic Pain by University Health Network, Toronto, or all of them as a file.
02

Study summary

Phase III Multicentre, parallel-group, blinded, 1:1 randomized controlled trial to determine the effect of perioperative vitamin C supplementation on reducing the prevalence of persistent pain 3 months after total knee arthroplasty.

Read the detailed description

PROVISION is a multicentre, parallel-group, blinded, randomized controlled trial of 3,216 patients undergoing total knee arthroplasty surgery. Consented eligible patients will be randomized to receive vitamin C: 2000 mg taken orally within 4 hours of the start of surgery, followed by 500 mg of vitamin C taken twice daily from post-operative day 1 to day 56 (8 weeks). Patient in the control group will receive placebo cellulose capsules. Study medications will be prepared to look similar and labelled as per regulatory requirements. Patients will follow up on post-operative days 1-3, weeks 2,4,6, and 8 post-operatively, and at 3- and 12-months post-operatively to report on pain, opioid and analgesic consumption, medication adherence, adverse events, physical and emotional functioning, and quality of life outcomes.

03

Conditions studied

  • Chronic Pain
  • Knee Pain Chronic
  • Post Operative Pain
  • Osteoarthritis, Knee
04

Who can participate

The criteria were revised on the registry on Nov 13, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients >18 years old
  • Undergoing a unilateral or simultaneous bilateral primary total knee arthroplasty for advanced osteoarthritis of the knee.

Exclusion criteria

Exclusion Criteria:

  • TKA for infection (septic joint), fracture, ankylosing spondylitis, lupus, or psoriatic arthritis
  • History of kidney stones, acute or chronic renal failure, hemochromatosis, or glucose-6-phosphate deficiency
  • Unlikely to comply with follow-up (e.g., no fixed address, plans to move out of town)
  • Language difficulties that would impede valid completion of questionnaires
  • Planned staged bilateral TKA
  • Treating surgeon deems patient inappropriate for inclusion in trial
  • Unwilling to abstain from non-study vitamin C during trial except for up to 100 mg/day contained in a routinely used multivitamin
  • Pregnant or planning to become pregnant during the study
05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
3,216 participants (estimated)

Study arms

  • Experimental
    Intervention

    Preoperative Vitamin C capsules

    Drug: Vitamin C

  • Placebo comparator
    Placebo

    Preoperative placebo capsules

    Drug: Placebo

Interventions

  • DrugAscorbic AcidStudies of Ascorbic AcidAscorbic Acid pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Drug: Patients in the intervention group will receive 2g Vitamin C orally within 4 hours of the start of the surgery followed by 500 mg of Vitamin C to be taken orally twice a day from post-op day 1 to day 56.

    Also known as: Ascorbic Acid

  • DrugPlacebo

    Drug: Patients in the placebo group will receive identical placebo capsules taken orally within 4 hours of the start of the surgery followed by placebo capsules taken orally twice a day from post-op day 1 to day 56.

    Also known as: Cellulose

06

What researchers measure

Primary outcomes

  1. Prevalence of persistent pain

    Pain intensity measured using 0-10 Numeric Rating Scale (NRS) scale at rest and movement

    Time frame: 3 months

Secondary outcomes

  1. Prevalence of persistent pain

    Pain intensity measured using 0-10 Numeric Rating Scale (NRS) scale at rest and movement

    Time frame: 12 months

  2. Qualities and characteristics of persistent pain

    Pain qualities measured using the 0-10 scale of the Short Form McGill Pain Questionnaire 2 (SF-MPQ-2)

    Time frame: 3 months and 12 months

  3. Persistent Neuropathic Pain

    Neuropathic pain assessed on a binary scale of Yes or No using the Douleur Neuropathique 4 (DN4) symptoms interview

    Time frame: 3 months and 12 months

  4. Acute and chronic analgesic consumption

    Analgesic and oral morphine-equivalent opioid consumption

    Time frame: Day of surgery, post-operative day 1-3, 3 months, and 12 months

  5. Development of Complex Regional Pain Syndrome (CRPS)

    Presence of CRPS measured by a physical assessment of sensory, vasomotor, sudomotor/edema, and motor/tropic categories using the Budapest Criteria

    Time frame: 3 months and 12 months

  6. Physical function

    Patient reported outcome measure to assess level of function, daily living activities and their affect on pain measured by answering 12 questions using the Oxford Knee Score (OKS)

    Time frame: 3 months and 12 months

  7. Emotional functioning

    Patients emotional functioning measured on a scale of 1-5 using the EQ-5D-5L

    Time frame: 3 months and 12 months

  8. Patient Satisfaction

    Assessment of patient satisfaction with surgery on scale of 0-100

    Time frame: 3 months and 12 months

  9. Quality of life assessment

    Patient reported assessment of mobility, self-care, usual activities, pain/discomfort, and anxiety/depression on a scale of level 1 - level 5 using the EuroQol 5-dimension 5-level (EQ-5D-5L)

    Time frame: 3 months and 12 months

  10. Adverse events

    Monitored as a secondary safety outcome using an assessment of follow-up visits for drug related adverse events and passive surveillance of clinical notes

    Time frame: 3 months and 12 months

07

Study locations

3 of 3 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2024 (actual). Primary completion is estimated for Dec 2029, 68 months after the start.

Of 49 phase 3 interventional studies under Chronic Pain, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 56. This study's planned 68 months is above that.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 13, 2026: primary completion Dec 2026 → Dec 2029 and completion Dec 2027 → Dec 2030.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Oct 10, 2023
First posted
Nov 9, 2023
StartActual
Apr 16, 2024
Primary completionEst.
Dec 31, 2029was Dec 2026
CompletionEst.
Dec 31, 2030was Dec 2027
Last update
Nov 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Dec 31, 2026→Dec 31, 2029
Nov 13, 2026
Study completion
Dec 31, 2027→Dec 31, 2030
Nov 13, 2026
Enrollment
400→3216
Nov 13, 2026
Eligibility
1 inclusion criterion edited; 1 exclusion criterion added, 1 removed
What changed in the criteria
Inclusion criteria
  • EditedUndergoing a unilateral or simultaneous bilateral primary total knee arthroplasty for advanced osteoarthritis of the knee.
Exclusion criteria
  • RemovedAny allergy or sensitivity to milk
  • AddedUnwilling to abstain from non-study vitamin C during trial except for up to 100 mg/day contained in a routinely used multivitamin
Nov 13, 2026
Primary outcomes
1 added, 3 removed
What changed in the outcomes
  • AddedPrevalence of persistent painTime frame: 3 months
  • RemovedStudy will determine feasibility of enrolling, recruiting, and follow-up with patients.Time frame: 12 months
  • RemovedClinical site complianceTime frame: 12 months
  • RemovedResource AssessmentTime frame: 12 months
Nov 13, 2026
Secondary outcomes
1 time frame changed
What changed in the outcomes
  • Time framePrevalence of persistent pain3 months and 12 months → 12 months
Nov 13, 2026
Design
Phase 2→Phase 3
Nov 13, 2026
Show all 1 update
  1. Nov 13, 2026
    Primary completion Dec 31, 2026→Dec 31, 2029
    Study completion Dec 31, 2027→Dec 31, 2030
    Enrollment 400→3216
    Eligibility 1 inclusion criterion edited; 1 exclusion criterion added, 1 removed
    What changed in the criteria
    Inclusion criteria
    • EditedUndergoing a unilateral or simultaneous bilateral primary total knee arthroplasty for advanced osteoarthritis of the knee.
    Exclusion criteria
    • RemovedAny allergy or sensitivity to milk
    • AddedUnwilling to abstain from non-study vitamin C during trial except for up to 100 mg/day contained in a routinely used multivitamin
    Primary outcomes 1 added, 3 removed
    What changed in the outcomes
    • AddedPrevalence of persistent painTime frame: 3 months
    • RemovedStudy will determine feasibility of enrolling, recruiting, and follow-up with patients.Time frame: 12 months
    • RemovedClinical site complianceTime frame: 12 months
    • RemovedResource AssessmentTime frame: 12 months
    Secondary outcomes 1 time frame changed
    What changed in the outcomes
    • Time framePrevalence of persistent pain3 months and 12 months → 12 months
    Design Phase 2→Phase 3
    + 7 other changes: index terms, identifiers, oversight details, description, conditions, arm descriptions and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06123715
Collaborators
Canadian Institutes of Health Research (CIHR), The Arthritis Society, Canada
Responsible party
Sponsor
First posted
Nov 9, 2023
Start date
Apr 16, 2024
Primary completion
Dec 31, 2029 (estimated)
Completion
Dec 31, 2030 (estimated)
Last update
Nov 13, 2026

Study contacts

James Khan, MD
Contact
James.Khan@medportal.ca
416-340-4800 ext. 3243
Nour Ayach
Contact
Nour.Ayach@uhn.ca
(416) 340 4800 ext. 4221
James Khan, MD
principal investigator · University Health Network; Department of Anesthesia and Pain Medicine
Raman Mundi, MD
principal investigator · Holland Orthopedic and Arthritic Centre
Harman Chaudhry, MD
principal investigator · Holland Orthopedic and Arthritic Centre
Jesse Wolfstadt, MD
principal investigator · Mount Sinai Hospital; Department of Surgery

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ascorbic Acid

Start the discussion